The immunological bone marrow (BM) microenvironment plays a major role in controlling growth and survival of clonal plasma cells (PC); this might translate into different patterns of expression of molecules involved in immune responses on PC from different types of monoclonal gammopathies (MG). We have studied the expression of a group of nine such molecules on both BMPC and the plasma of 61 newly diagnosed MG patients (30 MG of undetermined significance (MGUS), 27 multiple myeloma (MM) and four plasma cell leukemia (PCL)) and five normal individuals. Clonal PC from all MG displayed significantly increased levels of CD56, CD86 and CD126, and decreased amounts of CD38 (Po0.001). Additionally, HLA-I and b2-microglobulin were abnormally highly expressed in MGUS, while CD40 expression was decreased in MM and PCL (Po0.05). Interestingly, a progressive increase in the soluble levels of b2-microglobulin was found from MGUS to MM and PCL patients (P ¼ 0.03). In contrast, all groups showed similar surface and soluble amounts of CD126, CD130 and CD95, except for increased soluble levels of CD95 observed in PCL. Overall, those phenotypic differences are consistent with increased antigen presentation and costimulatory capacities in MGUS, which progressively deteriorate in malignant MG (MM and PCL).
Introduction
Monoclonal gammopathies (MG) show a variable clinical and biological behavior, ranging from the more benign forms, the socalled MG of undetermined significance (MGUS), to multiple myeloma (MM), and plasma cell leukemia (PCL), the most aggressive form of MG. [1] [2] [3] [4] [5] [6] [7] [8] To date such heterogeneity could not be explained on genetic grounds since most genetic alterations detected so far can be found in the three entities. [8] [9] [10] Otherwise, increasing evidences exist, supporting the notion that some of the earliest oncogenic events differentially affect the interaction of plasma cells (PC) with the bone marrow (BM) microenvironment, including its immunological components. [11] [12] [13] Accordingly, cytokines such as interleukin 6 (IL-6), cell surface receptors and adhesion molecules that facilitate a close contact between myeloma cells and marrow stromal components have been involved in sustaining PC proliferation, survival and drug resistance. 3, 4, [10] [11] [12] [13] [14] [15] On the other hand, MM clonal PC have been shown to express antigen presentation proteins 16 as well as molecules involved in the costimulation of T cells (eg CD40 and CD86). [17] [18] [19] [20] In addition to cellular molecules, multiple soluble factors have also been involved in the pathogenesis of the disease, since they are released into the extracellular media promoting tumor cell accumulation, drug resistance and an immunodeficiency state. 21 In line with these observations, both the cellular and soluble levels of the HLA-I molecules and the IL-6 receptor (IL-6R) chains, as well as the expression of costimulatory (CD40, CD80 and CD86) and adhesion (eg CD38) molecules and the CD95 death-related receptor have been associated with disease activity and/or an impaired immune response in MM. 4, 17, [22] [23] [24] [25] [26] [27] [28] Despite this, to date no systematic studies have been performed in which the relationship between the expression of such molecules at cellular and soluble levels and the benign vs malignant behavior of MG has been analyzed.
In the present study, we hypothesize that, if the immunological BM microenvironment plays a major role in controlling tumor growth, survival and drug resistance of clonal PC, this may translate into different patterns of expression of molecules involved in immune responses among patients with different forms of MG. In order to test this hypothesis, we have comparatively analyzed the quantitative expression of molecules related to the immune system both on the PC membrane and in the plasma of patients with MGUS, MM and PCL, including antigen-presenting molecules, cytokines receptors, adhesion and costimulatory molecules and cell death receptors.
Materials and methods

Patients and controls
A total of 61 patients with nontreated MG diagnosed according to previously described criteria 2 were included in this study. From them, 30 corresponded to MGUS (24 males and six females with a mean age of 70711 years), 27 to MM (18 males and nine females aged 71710 years) and four were PCL (one male and three females with a mean age of 6979 years).
A group of five age-and sex-matched volunteers who underwent orthopedic surgery and did not have any systemic disorders was studied in parallel and used as normal controls.
In all cases, BM samples were obtained after informed consent according to the local Ethical Committees.
Immunophenotypic studies
Whole BM samples (1-2 Â 10 6 cells in 100 ml/test) collected in EDTA were stained using direct immunofluorescence with the following monoclonal antibodies (MAb) in four-color combinations (fluorescein isothiocyanate, phycoerythrin (PE), the PE/ cyanin 5 (PE/Cy5) fluorochrome tandem and allophycocyanin (APC)), which systematically included CD38 for the specific identification of BMPC: HLA-I, CD40 and CD126 (Immunotech, Marseille, France), CD38, CD80 and CD95 (Becton/Dickinson Biosciences -BDB, San Jose, CA, USA); CD86 and CD130 (Pharmingen, San Diego, CA, USA), CD19 (Caltag Laboratories, San Francisco, CA, USA), b2-microglobulin (Cymbus Biotechnology Ltd, Hampshire, UK), and CD138 and CD56 (Vitro, Madrid, Spain).
Data acquisition was performed in a FACSCalibur flow cytometer (BDB). In all BM samples witho15% PC, acquisition was performed in two consecutive steps. Firstly, a total of 30 000 events/tube were acquired; in the second step, acquisition through a 'live-gate' drawn to collect only those events showing intermediate side scatter (SSC) values and strong CD38 expression (where PCs are located) was performed. In this latter step, information on a minimum of 5 Â 10 3 PC corresponding to 410 5 BM cells was specifically stored. For data analysis, the Paint-A-Gate PRO software (BDB) was used. PCs were identified according to their positivity for CD138 together with their strong reactivity for CD38 and their typical light-scatter distribution. 4 Discrimination between normal and pathological PC was performed on the basis of their different patterns of expression of CD38, CD19 and CD56, and SSC/forward scatter values, as described. 4 Since PCs usually display a higher level of autofluorescence with respect to other nucleated BM cells, an FL1/FL2 unlabeled plus CD138-PE/Cy5/CD38-APC was used as negative control to evaluate the green and orange PC autofluorescence levels. Antigen expression was evaluated for each molecule and both the percentage of positive PCs and the mean fluorescence intensity (MFI; expressed as arbitrary relative linear fluorescence channel units scaled from 0 to 10 4 ) recorded.
Analysis of soluble protein plasma levels
Plasma was collected from PB samples and immediately stored at À801C until further processed. Soluble plasma levels of CD126 (IL-6R), CD130 and CD95 were measured using commercially available ELISA kits (Quantikine, R&D systems, Inc., Minneapolis, MN, USA) and b2-microglobulin was quantified with the Immulite b2m kit (Diagnostic Products Corporation, Los Angeles, CA, USA). Soluble levels of HLA-I (sHLA-I) were measured by a previously described ELISA approach, 29 
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MAb clone (kindly provided by ML Villar; Madrid, Spain) labeled with biotin was employed afterwards for the recognition of b2-microglobulin. ELISA Plates were read using an UV-max ELISA plate reader (ICN Flow Laboratories, Irvine, UK) at a 450 nm excitation wavelength.
Statistical methods
The Mann-Whitney U-test and Kruskal-Wallis test were used for the evaluation of statistical significance of the differences between groups. Correlation studies were performed using the Spearman test. P-values p0.05 were considered to be associated with statistical significance.
Results
Immunophenotype of normal PC from MGUS patients and control individuals
The mean percentage of normal BMPC was similar in control donors and MGUS patients (0.3370.12 vs 0.2570.17;
In addition, no statistically significant phenotypic differences were found between normal BMPC from healthy individuals and MGUS for the molecules analyzed even when we considered the MFI per PC (Figure 1 ). Accordingly, normal BMPC from both groups of individuals were constantly positive for the HLA-I and b2-microglobulin, they expressed high levels of CD38 and CD40, showed variable reactivity for CD56 and CD86 and they were constantly CD80 À . Regarding expression of the IL-6R chains on normal BMPC from both controls and MGUS, CD130 was constantly dimly expressed while undetectable levels of CD126 were found. Finally, expression of CD95 was positive at low intensity.
Immunophenotypic differences between normal PC and clonal PC from MGUS patients 
Immunophenotype of clonal PC in MGUS as compared to MM and PCL
Clonal BMPC from MGUS showed a significantly different phenotype from that of clonal PC from both MM and PCL (Figure 2) . Accordingly, clonal BMPC from MGUS showed significantly higher levels of both HLA-I and b2-microglobulin molecules as compared to MM and PCL PC (MFI per PC of 709272015 vs 518572221 and 390572525 (P ¼ 0.02) and 11787978 vs 5987744 and 2097161 (P ¼ 0.01), respectively). It should be noted that the median amount of HLA-I and b2-microglobulin per BMPC tended to be lower in PCL as compared to MM cases, although differences did not reach statistical significance. In a similar way, significantly lower CD38 and CD40 levels were observed in BMPC from MM and PCL as compared to MGUS (MFI per PC of 572872106 in MGUS vs 406471856 and 238771119 in MM and PCL, respectively, P ¼ 0.001; and MFI per PC of 9527540 in MGUS vs 5417308 and 6057303 in MM and PCL, respectively, P ¼ 0.05).
In all three groups of MG, clonal BMPC showed a significantly increased expression of CD56 þ , CD86 þ and CD126 þ as compared to normal BMPC; however, no statistically significant differences in the expression of these molecules was observed, either in terms of the percentage of positive cells or MFI values between the three groups ( Figure 2) .
The pattern of expression of CD130 and CD80 was not statistically significantly different among the three groups of MG patients. Finally, it should be noted that despite no statistically significant differences were observed for CD95 expression, BMPC from two of the four PCL expressed abnormally higher levels of CD95 (Figure 2 ). Phenotypic differences between PC from MGUS, MM and PCL M Pérez-Andrés et al (3.673.7 ng/ml; Po0.001) to MM (6.276.2 ng/ml; Po0.001) and PCL (13.079.0 mg/l; P ¼ 0.02) (Figure 3 ). In contrast, no statistically significant differences were observed between the different groups of patients and controls, for the other molecules analyzed (sCD126, sCD130, sCD95, sHLA-I), except for increased sHLA-I plasma levels found in PCL patients, as compared to the control group (Figure 3) .
Plasma levels of soluble molecules in MGUS as compared to MM and PCL
Correlation between expression of surface molecules on BMPC and their plasma levels in MGUS as compared to MM and PCL
Overall, a positive correlation between cell surface and plasma levels of CD95 (Fas) was found in MG cases (r 2 ¼ 0.34; P ¼ 0.04) ( Figure 4) ; such correlation retained its statistical significance once MGUS patients were separately considered (r 2 ¼ 0.72; P ¼ 0.03). In a similar way, an inverse correlation was found for surface and soluble levels of b2-microglobulin (r 2 ¼ À0.50; Po0.001) in all MG cases, such correlation decreasing its statistical significance in individual patient groups: MGUS, r 2 ¼ À0.42 (P ¼ 0.08); MM, r 2 ¼ À0.34 (P ¼ 0.09); and PCL, r 2 ¼ À0.50 (P ¼ 0.67). No correlation between surface and plasma levels of HLA-I and both IL-6R chains analyzed was found, neither when considering the different groups of patients separately nor once they were grouped together.
In turn, the ratio between soluble and cell surface amounts of the HLA-I and b2-microglobulin molecules progressively increased from MGUS to MM (P ¼ 0.03 and 0.008, respectively), and PCL (P ¼ 0.04 and 0.03) ( Figure 5 ). In contrast, the relationship between the cell surface and soluble levels of the CD126 and CD130 IL-6R chains was similar in the three patients groups ( Figure 5 ).
Discussion
Up till now, immunophenotypic studies have shown no major differences between clonal BMPC from patients with different types of MG. 4, 7 However, a detailed analysis of these results shows that in most comparative studies between MGUS, MM and PCL, PC molecules involved in antigen presentation and T-cell costimulation have not been analyzed. 19, 22 In the present study, we show that important changes occur in the expression of soluble and surface PC proteins involved in mediating antigen presentation and costimulation of T cells in patients with MG. Interestingly, such changes are not common to all types of MG, but they vary between MGUS, MM and PCL. Accordingly, clonal BMPC in MGUS displayed a significant increase in HLA-I antigen-presenting molecules, which progressively decreased in aggressive forms of MG, MM and PCL, in association with an increase in their soluble levels. This determined a higher ratio between soluble and cellular levels of b2-microglobulin and HLA-I, probably due to cleavage of both proteins from the cellular membrane into the extracellular medium. 30 To the best of our knowledge, this is the first time that differential expression of HLA-I molecules on clonal PC from different types of MG is reported. Interestingly, it would be consistent with an increase in antigen presentation to cytotoxic T cells in neoplastic PC in MGUS, in line with previous findings showing the ability of T cells from MGUS to build up vigorous immune responses without the need for prolonged in vitro expansions. 31 In turn, in MM and PCL patients, the decreased expression of HLA-I molecules on the surface of BMPC could diminish the number of tumor-associated peptides presented to T cells. The progressive increase of soluble b2-microglobulin and HLA-I molecules could further interfere with T and NK functionality in advanced forms of MG as they have been shown to induce apoptosis of T and NK cells in vitro, 32, 33 and affect dendritic cells' function. 34 An altered expression of antigen-presenting molecule in different stages of the disease has also been reported in other types of cancer. 35 Based on these observations, it has been proposed that in the initial preclinic phase of many tumors, an increased expression of HLA-I molecules due to immunological signaling (ie by g-IFN)
36 would occur; later on, after an equilibrium period HLA-I-defective neoplastic cells would be selected facilitating tumor progression into clinically aggressive forms. 36 In addition to HLA-peptide complexes, costimulatory molecules play a crucial role during antigen presentation to T cells and the induction of effective antigen-specific T cells response. Among others, CD40 is one such costimulatory molecules expressed by PC. Stimulation of CD40 on myeloma PC has been shown to induce upregulation of other costimulatory molecules 'in vitro' and potentially 'in vivo'. 37 In the present study, we confirm that CD40 is expressed by both normal and neoplastic PC; however, we show that reactivity for CD40 on clonal PC is significantly decreased in MM and PCL, whereas normal in MGUS. These findings, together with the 'in vitro' evidence that apoptosis and immune responses are enhanced after upregulating CD40 expression on malignant PC, 37, 38 would suggest that the 'in vivo' reduction on CD40 expression might contribute to a deficient crosstalk between PC and immune cells in more Correlation between surface and soluble levels of b2-microglobulin and CD95 in patients with MG. Spearman's test was used to evaluate the statistical significance of correlation observed between variables.
Phenotypic differences between PC from MGUS, MM and PCL M Pérez-Andrés et al advanced forms of MG. In contrast to CD40, we found that expression of the CD86 costimulatory molecule was significantly increased in clonal PC from all MG as compared to that of normal BMPC; in contrast, both clonal and normal PC lacked on CD80 expression. The role of the CD80 and CD86 costimulatory molecules in MG is uncertain. Although it is generally established that upregulation of both molecules could help in stimulating effective immune responses, recent studies have shown that in clonal PC, upregulation of CD80 is able to better enhance a greater antitumor T-cell-mediated immune responses than upregulation of CD86 does. 17, 39 Moreover, CD86 expression by clonal PC has been related with poor prognosis in MM patients. 22 Interestingly, the changes observed on the expression of HLA class I and costimulatory molecules in MG patients were associated with a significant increased and stable expression of the IL-6R a-chain (CD126) on the surface of both benign and malignant clonal PC. In contrast to what was observed for the distribution of HLA class I molecules in the cellular and soluble compartments of malignant PC conditions, increased expression of CD126 on PC was not associated with a higher ratio between soluble and cellular CD126. Altogether, these findings could reflect an overall higher susceptibility of clonal PC to respond to stimulatory signals mediated through IL-6 independently of the type of MG.
High CD38 expression has long been considered as a hallmark of PC, this marker being commonly used for the identification of both normal and clonal PC. 4 Despite this, it has been shown that myeloma PC display aberrantly low levels of CD38 as compared to their normal BM counterpart. 4, 5 In the present study, we confirm and extend these observations showing a progressive decreased expression of CD38 from normal to clonal BMPC of MGUS, MM and PCL. CD38 is a multifunctional molecule able to transduce signals involving cell proliferation and differentiation and mediate adherence to hyaluronan and other ligands, 40, 41 among other functions. Altogether, these findings suggest a major role of CD38 in the interaction between PC and the BM microenvironment, which may influence the fate of malignant PC and facilitate the massive migration to PB observed in PCL. Further studies are necessary to elucidate the exact functional role of this molecule in normal and neoplastic PC.
In contrast, no change of CD95 expression was observed in clonal PC, although soluble levels of this molecule were increased in PCL, which may suggest a protective effect for survival of sCD95 in these patients. 42 In summary, in the present study, we demonstrate that among patients with MG, important phenotypic differences in neoplastic PC are observed in the distinct forms of the disease, as regards the expression of antigen-presenting proteins and costimulatory molecules. Such differences are consistent with an increased antigen-presenting and costimulatory capacity in MGUS, which progressively deteriorates in MM and PCL. Ratio between the soluble amount and PC surface levels of the HLA-Ia and b2-microglobulin antigen-presenting molecules (upper panels) and of the CD126 and CD130 IL-6R chains (lower panels). n, Statistically significant different (Pp0.05) from MGUS.
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